G&A at other companies
Other financials
Where this comes from
Reported directly by Monopar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The official record: Monopar Therapeutics’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Monopar Therapeutics's g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Monopar Therapeutics's G&A?
- Monopar Therapeutics (MNPR) reported G&A of $1.74M in Q1 2026.
- How has Monopar Therapeutics's G&A changed year-over-year?
- Monopar Therapeutics's G&A increased by 10.1% year-over-year, from $1.58M to $1.74M.
- What is the long-term trend for Monopar Therapeutics's G&A?
- Over 4 years (2021 to 2025), Monopar Therapeutics's G&A has grown at a 26.8% compound annual growth rate (CAGR), from $2.63M to $6.8M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.